LOGIN  |  REGISTER
Viking Therapeutics

Information on the Total Number of Voting Rights and Shares

March 31, 2023 | Last Trade: US$8.00 0.00 0.00

Mont-Saint-Guibert (Belgium), March 31, 2023, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.

  •  Share capital: EUR 4,859,382.45 
  •  Total number of securities carrying voting rights: 28,286,985 (all ordinary shares) 
  •  Total number of voting rights (= denominator): 28,286,985 (all relating to ordinary shares)  
  •  Number of rights to subscribe to securities carrying voting rights not yet issued: 
    •  55 “2016 ESOP Warrants” issued on November 3, 2016, entitling their holders to subscribe to a total number of 27,500 securities carrying voting rights (all ordinary shares); 
    •  100 “2018 ESOP Warrants” issued on December 12, 2018, entitling their holders to subscribe to a total number of 50,000 securities carrying voting rights (all ordinary shares);  
    •  430,500 “2020 ESOP Warrants” issued on February 21, 2020, entitling their holders to subscribe to a total number of 430,500 securities carrying voting rights (all ordinary shares); and
    •  1,326,375 “2021 ESOP Warrants” issued on September 8, 2021, entitling their holders to subscribe to a total number of 1,326,375 securities carrying voting rights (all ordinary shares); and
    •  700,000 “2022 ESOP Warrants” issued on December 28, 2022, entitling their holders to subscribe to a total number of 700,000 securities carrying voting rights (all ordinary shares).  

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 310 310 1313


Chimerix

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB